CGG repeat in the FMR1 gene: Size matters

Clinical Genetics

Volumn 80, Issue 3, 2011, Pages 214-225

  Willemsen, R ^a   Levenga, J ^a   Oostra, B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CGG repeat; FMR1; FXPOI; FXTAS; Mental retardation; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID; AFQ 56; ARBACLOFEN; FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA; METABOTROPIC RECEPTOR ANTAGONIST; MINOCYCLINE; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; CGG REPEAT; DEGENERATIVE DISEASE; DENDRITIC CELL; DNA METHYLATION; DNA STRUCTURE; FRAGILE X SYNDROME; FRAGILE X TREMOR ATAXIA SYNDROME; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENE STRUCTURE; HETEROZYGOTE; HUMAN; MENTAL DEFICIENCY; NONHUMAN; OVARY INSUFFICIENCY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TRANSPORT; REVIEW; TRANSLATION REGULATION;

5' UNTRANSLATED REGIONS; AGED; ANIMALS; ATAXIA; BRAIN; DISEASE MODELS, ANIMAL; DNA METHYLATION; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MICE; MICE, KNOCKOUT; NEURONS; PHENOTYPE; PRESCRIPTION DRUGS; PRIMARY OVARIAN INSUFFICIENCY; TRINUCLEOTIDE REPEATS;

EID: 79961128595     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2011.01723.x     Document Type: Review

References (112)

1. Verkerk AJ, Pieretti M, Sutcliffe JS et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991: 65: 905-914.
2. Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Silverman AC, eds. Fragile X syndrome: diagnosis, treatment and research. Baltimore and London: The John Hopkins University Press, 1996: 3-87.
3. Merenstein SA, Sobesky WE, Taylor AK et al. Molecular-clinical correlations in males with an expanded FMR1 mutation. Am J Med Genet 1996: 64: 388-394.
4. Yu S, Pritchard M, Kremer E et al. Fragile X genotype characterized by an unstable region of DNA. Science 1991: 252: 1179-1181.
5. Oberlé I, Rousseau F, Heitz D et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 1991: 252: 1097-1102.
6. Bell MV, Hirst MC, Nakahori Y et al. Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell 1991: 64: 861-866.
7. Chiurazzi P, Neri G. Reactivation of silenced genes and transcriptional therapy. Cytogenet Genome Res 2003: 100: 56-64.
8. Pietrobono R, Tabolacci E, Zalfa F et al. Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet 2005: 14: 267-277.
9. Eiges R, Urbach A, Malcov M et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 2007: 1: 568-577.
10. Brouwer JR, Willemsen R, Oostra BA. Microsatellite repeat instability and neurological disease. Bioessays 2009: 31: 71-83.
11. Willemsen R, Oostra BA, Bassell GJ et al. The fragile X syndrome: from molecular genetics to neurobiology. Ment Retard Dev Disabil Res Rev 2004: 10: 60-67.
12. Darnell JC, Jensen KB, Jin P et al. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 2001: 107: 489-499.
13. Darnell JC, Fraser CE, Mostovetsky O et al. Kissing complex RNAs mediate interaction between the fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev 2005: 19: 903-918.
14. Christie SB, Akins MR, Schwob JE et al. The FXG: a presynaptic Fragile X granule expressed in a subset of developing brain circuits. J Neurosci 2009: 29: 1514-1524.
15. Kiebler MA, Bassell GJ. Neuronal RNA granules: movers and makers. Neuron 2006: 51: 685-690.
16. Pacey LK, Doering LC. Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome. Glia 2007: 55: 1601-1609.
17. Jacobs S, Doering LC. Astrocytes prevent abnormal neuronal development in the fragile X mouse. J Neurosci 2010: 30: 4508-4514.
18. De Diego Otero Y, Severijnen LA, Van Cappellen G et al. Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol Cell Biol 2002: 22: 8332-8341.
19. Steward O, Bakker CE, Willems PJ et al. No evidence for disruption of normal patterns of mRNA localization in dendrites or dendritic transport of recently synthesized mRNA in FMR1 knockout mice, a model for human fragile-X mental retardation syndrome. Neuroreport 1998: 9: 477-481.
20. Dictenberg JB, Swanger SA, Antar LN et al. A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev Cell 2008: 14: 926-939.
21. Feng Y, Absher D, Eberhart DE et al. FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol Cell 1997: 1: 109-118.
22. De Boulle K, Verkerk AJ, Reyniers E et al. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet 1993: 3: 31-35.
23. Levenga J, Buijsen RA, Rife M et al. Ultrastructural analysis of the functional domains in FMRP using primary hippocampal mouse neurons. Neurobiol Dis 2009: 35: 241-250.
24. Schrier M, Severijnen LA, Reis S et al. Transport kinetics of FMRP containing the I304N mutation of severe fragile X syndrome in neurites of living rat PC12 cells. Exp Neurol 2004: 189: 343-353.
25. Laggerbauer B, Ostareck D, Keidel EM et al. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 2001: 10: 329-338.
26. Weiler IJ, Spangler CC, Klintsova AY et al. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc Natl Acad Sci USA 2004: 101: 17504-17509.
27. Narayanan U, Nalavadi V, Nakamoto M et al. S6K1 phosphorylates and regulates FMRP with the neuronal protein synthesis-dependent mTOR signaling cascade. J Biol Chem 2008: 283: 18478-18482.
28. Ceman S, O'Donnell WT, Reed M et al. Phosphorylation influences the translation state of FMRP-associated polyribosomes. Hum Mol Genet 2003: 12: 3295-3305.
29. Narayanan U, Nalavadi V, Nakamoto M et al. FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A. J Neurosci 2007: 27: 14349-14357.
30. Ishizuka A, Siomi MC, Siomi H. A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev 2002: 16: 2497-2508.
31. Jin P, Zarnescu DC, Ceman S et al. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci 2004: 7: 113-117.
32. Lugli G, Torvik VI, Larson J et al. Expression of microRNAs and their precursors in synaptic fractions of adult mouse forebrain. J Neurochem 2008: 106: 650-661.
33. Edbauer D, Neilson JR, Foster KA et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 2010: 65: 373-384.
34. Greco CM, Navarro CS, Hunsaker MR et al. Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome. Mol Autism 2011: 2: 2.
35. Irwin SA, Patel B, Idupulapati M et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet 2001: 98: 161-167.
36. Comery TA, Harris JB, Willems PJ et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci USA 1997: 94: 5401-5404.
37. Irwin SA, Idupulapati M, Gilbert ME et al. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am J Med Genet 2002: 111: 140-146.
38. Nimchinsky EA, Oberlander AM, Svoboda K. Abnormal development of dendritic spines in fmr1 knock-out mice. J Neurosci 2001: 21: 5139-5146.
39. Galvez R, Greenough WT. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am J Med Genet A 2005: 135: 155-160.
40. Grossman AW, Elisseou NM, McKinney BC et al. Hippocampal pyramidal cells in adult Fmr1 knockout mice exhibit an immature-appearing profile of dendritic spines. Brain Res 2006: 1084: 158-164.
41. Antar LN, Li C, Zhang H et al. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol Cell Neurosci 2006: 32: 37-48.
42. De Vrij FMS, Levenga J, Van der Linde HC et al. Rescue of behavioral phenotype and neuronal protrusion morphology in FMR1 KO mice. Neurobiol Dis 2008: 31: 127-132.
43. Bakker CE, Verheij C, Willemsen R et al. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994: 78: 23-33.
44. Mientjes EJ, Nieuwenhuizen I, Kirkpatrick L et al. The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis 2006: 21: 549-555.
45. Musumeci SA, Bosco P, Calabrese G et al. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 2000: 41: 19-23.
46. Kooy RF. Of mice and the fragile X syndrome. Trends Genet 2003: 19: 148-154.
47. Bakker CE, Oostra BA. Understanding fragile X syndrome: insights from animal models. Cytogenet Genome Res 2003: 100: 111-123.
48. Zhang YQ, Bailey AM, Matthies HJ et al. Drosophila fragile X-related gene regulates the MAP1B homolog futsch to control synaptic structure and function. Cell 2001: 107: 591-603.
49. Bushey D, Tononi G, Cirelli C. The Drosophila fragile x mental retardation gene regulates sleep need. J Neurosci 2009: 29: 1948-1961.
50. McBride SM, Choi CH, Wang Y et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005: 45: 753-764.
51. Tucker B, Richards RI, Lardelli M. Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum Mol Genet 2006: 15: 3446-3458.
52. den Broeder MJ, van der Linde H, Brouwer JR et al. Generation and characterization of FMR1 knockout zebrafish. PLoS One 2009: 4: e7910.
53. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004: 27: 370-377.
54. D'Hulst C, Kooy RF. The GABA(A) receptor: a novel target for treatment of fragile X? Trends Neurosci 2007: 30: 425-431.
55. Chang S, Bray SM, Li Z et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 2008: 4: 256-263.
56. D'Hulst C, De Geest N, Reeve SP et al. Decreased expression of the GABA(A) receptor in fragile X syndrome. Brain Res 2006: 1121: 238-245.
57. Jacquemont S, Curie A, des Portes V et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011: 3: 64ra61.
58. Levenga J, Hayashi S, de Vrij FM et al. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 2011: 42: 311-317.
59. Levenga J, de Vrij FM, Oostra BA et al. Potential therapeutic interventions for fragile X syndrome. Trends Mol Med 2010: 16: 516-527.
60. Dolen G, Carpenter RL, Ocain TD et al. Mechanism-based approaches to treating fragile X. Pharmacol Ther 2010: 127: 78-93.
61. Heulens I, Kooy F. Fragile X syndrome: from gene discovery to therapy. Front Biosci 2011: 16: 1211-1232.
62. Hagerman PJ. The fragile X prevalence paradox. J Med Genet 2008: 45: 498-499.
63. Tassone F, Beilina A, Carosi C et al. Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA 2007: 13: 555-562.
64. Tassone F, De Rubeis S, Carosi C et al. Differential usage of transcriptional start sites and polyadenylation sites in FMR1 premutation alleles. Nucleic Acids Res 2011: doi: 10.1093/nar/gkr100 (Epub ahead of print).
65. Hagerman RJ, Leehey M, Heinrichs W et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001: 57: 127-130.
66. Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med 2009: 57: 830-836.
67. Kamm C, Healy DG, Quinn NP et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005: 128: 1855-1860.
68. Greco CM, Berman RF, Martin RM et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006: 129: 243-255.
69. Hagerman RJ, Leavitt BR, Farzin F et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004: 74: 1051-1056.
70. Jacquemont S, Hagerman RJ, Leehey MA et al. Penetrance of the fragile x-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004: 291: 460-469.
71. Garcia Arocena D, Louis ED, Tassone F et al. Screen for expanded FMR1 alleles in patients with essential tremor. Mov Disord 2004: 19: 930-933.
72. Grigsby J, Brega AG, Seritan AL et al. FXTAS: neuropsychological/neuropsychiatric phenotypes. In: Tassone F, Berry-Kravis EM, eds. The fragile X-associated tremor ataxia syndrome (FXTAS). New York: Springer, 2010: 31-54.
73. Greco CM, Soontrapornchai K, Wirojanan J et al. Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. J Urol 2007: 177: 1434-1437.
74. Jacquemont S, Hagerman RJ, Leehey M et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003: 72: 869-878.
75. Greco CM, Hagerman RJ, Tassone F et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002: 125: 1760-1771.
76. Willemsen R, Hoogeveen-Westerveld M, Reis S et al. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet 2003: 12: 949-959.
77. Entezam A, Biacsi R, Orrison B et al. Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model. Gene 2007: 395: 125-134.
78. Hashem V, Galloway JN, Mori M et al. Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum Mol Genet 2009: 18: 2443-2451.
79. Entezam A, Usdin K. ATR protects the genome against CGG*CGG-repeat expansion in Fragile X premutation mice. Nucleic Acids Res 2007: 36: 1050-1056.
80. Entezam A, Usdin K. ATM and ATR protect the genome against two different types of tandem repeat instability in Fragile X premutation mice. Nucleic Acids Res 2009: 37: 6371-6377.
81. Entezam A, Lokanga AR, Le W et al. Potassium bromate, a potent DNA oxidizing agent, exacerbates germline repeat expansion in a Fragile X premutation mouse model. Hum Mutat 2010: 31: 611-616.
82. Brouwer JR, Mientjes EJ, Bakker CE et al. Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res 2007: 313: 244-253.
83. Brouwer JR, Huizer K, Severijnen LA et al. CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem 2008: 107: 1671-1682.
84. Hunsaker MR, Wenzel HJ, Willemsen R et al. Progressive spatial processing deficits in a mouse model of the fragile X premutation. Behav Neurosci 2009: 123: 1315-1324.
85. Wenzel HJ, Hunsaker MR, Greco CM et al. Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X premutation. Brain Res 2010: 1318: 155-166.
86. Van Dam D, Errijgers V, Kooy RF et al. Cognitive decline, neuromotor and behavioural disturbances in a mouse model for Fragile-X-associated tremor/ataxia syndrome (FXTAS). Behav Brain Res 2005: 162: 233-239.
87. Hunsaker MR, Goodrich-Hunsaker NJ, Willemsen R et al. Temporal ordering deficits in female CGG KI mice heterozygous for the fragile X premutation. Behav Brain Res 2010: 213: 263-268.
88. Qin M, Entezam A, Usdin K et al. A mouse model of the fragile X premutation: effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis. Neurobiol Dis 2011: 42: 85-98.
89. Jin P, Zarnescu DC, Zhang F et al. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron 2003: 39: 739-747.
90. Galloway JN, Nelson DL. Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome. Future Neurol 2009: 4: 785.
91. Todd PK, Oh SY, Krans A et al. Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet 2010: 6: e1001240.
92. Garcia-Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet 2010: 19: R83-R89.
93. Tassone F, Iwahashi C, Hagerman PJ. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol 2004: 1: 103-105.
94. Jin P, Duan R, Qurashi A et al. Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 2007: 55: 556-564.
95. Sofola OA, Jin P, Qin Y et al. RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 2007: 55: 565-571.
96. Arocena DG, Iwahashi CK, Won N et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet 2005: 14: 3661-3671.
97. Sellier C, Rau F, Liu Y et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. Embo J 2010: 29: 1248-1261.
98. Ladd PD, Smith LE, Rabaia NA et al. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 2007: 16: 3174-3187.
99. Garcia-Arocena D, Yang JE, Brouwer JR et al. Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet 2009: 19: 299-312.
100. Ross-Inta C, Omanska-Klusek A, Wong S et al. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J 2010: 429: 545-552.
101. Chen Y, Tassone F, Berman RF et al. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 2010: 19: 196-208.
102. Cunningham CL, Martinez Cerdeno V, Navarro E et al. Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. Hum Mol Genet 2011: 20: 64-79.
103. Aziz M, Stathopulu E, Callias M et al. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet 2003: 121: 119-127.
104. Farzin F, Perry H, Hessl D et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr 2006: 27: S137-S144.
105. Bailey DB Jr, Raspa M, Olmsted M et al. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A 2008: 16: 2060-2069.
106. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986: 67: 604-606.
107. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study - preliminary data. Am J Med Genet 1999: 83: 322-325.
108. Murray A. Premature ovarian failure and the FMR1 gene. Semin Reprod Med 2000: 18: 59-66.
109. Sullivan AK, Marcus M, Epstein MP et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005: 20: 402-412.
110. Allen EG, Sullivan AK, Marcus M et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 2007: 22: 2142-2152.
111. Brouwer JR, Willemsen R, Oostra BA. The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am J Med Genet B Neuropsychiatr Genet 2009: 150B: 782-798.
112. Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev 2002: 12: 278-283.